Teva can rest easy knowing that it does have a long runway free of generics—at least from two major challengers—as it focuses on the tardive dyskinesia drug Austedo for growth. Teva has settled its patent infringement action with Aurobindo Pharma over the latter’s application to commercialise a generic version of Austedo. Aurobindo has a licence to start selling its generic in the United States in April 2033 or early under specific conditions, according to the agreement.
Teva’s most valuable medicine is undoubtedly Austedo. Last year, the med raked in $802 million, a 26% increase over 2020. Another generic player has been held off until 2033 by the Israeli company. Teva and Lupin reached an agreement last month to let the latter sell its generic form of Austedo in April 2033. Last July, Teva filed lawsuits against Lupin and Aurobindo, alleging violation of numerous patents it controls.
Teva claims that Austedo is so far the only FDA-approved medication for chorea linked with Huntington’s disease and tardive dyskinesia. The medication was first approved by the FDA in 2017. According to a statement, Teva feels that the Aurobindo settlement is a reflection of the integrity of its property rights.
